Menu
close
Please contact us for more information or to learn if you are eligible to participate.
The objective of the study is to determine the feasibility of developing, producing and providing a personalized intravenous phage for Covid-19 patients who have pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
Principal Investigator | Sohail Rao, MD |
Sponsor | Adaptive Phage Therapeutics, Inc. |
Type of Trial | Interventional |